Jazz Pharmaceuticals And 2 Top Biotech Stocks To Watch

US inflation remains above the Federal Reserve's 2% target and higher gas prices are squeezing household budgets. That pressure often pushes investors to look for assets that do not move in lockstep with the broader economy. High risk biotech shares with solid finances can fit that brief. This article walks through three candidates from a focused biotech filter that many investors are watching closely right now.

The three biotech stocks below are just a starter set, and the same filter surfaced 86 more companies with equally compelling stories that are not covered here. To size up that wider universe, head straight into the Biotech Stocks screener to identify, compare, and analyze the highest conviction biotech opportunities.

Jazz Pharmaceuticals (JAZZ)

Jazz Pharmaceuticals brings together marketed cancer and CNS therapies with a deep biotech pipeline, giving this screen a mix of current cash flows and high risk, high potential drug programs that can matter for investors who want product driven exposure rather than broad economic sensitivity.

Jazz Pharmaceuticals focuses on oncology and central nervous system medicines such as Xywav, Epidiolex, Zepzelca and other biotech therapies, generating about US$4.6b in 2024 pharmaceutical product revenue, with a market value of roughly US$14b.

"Expected expansion of Ziihera across additional HER2 driven tumors, including biliary tract, colorectal, lung and early or metastatic breast cancer, following the raised US$3b to US$5b peak sales outlook, could add new oncology revenue streams and support higher long term earnings power."

What really matters now is how one pressure point behind those future cash flows shapes both pricing power and the durability of margins.

That pricing question is exactly what the full narrative for Jazz Pharmaceuticals unpacks in detail, including how competition, payers, and pipeline timing could be masking Jazz Pharmaceuticals’ true earnings potential.

Arrowhead Pharmaceuticals (ARWR)

Arrowhead Pharmaceuticals is one of the purest Biotech Stocks screen picks for RNA interference, with a long list of RNAi drug candidates in human trials that aim to turn high scientific risk into meaningful upside if the science and the commercial execution both work.

Arrowhead Pharmaceuticals develops RNAi based medicines for hard to treat diseases, with US$669 million of nanotechnology related revenue generated in the United States and a market value of about US$8.5b.

For investors hunting high-risk, high-reward biotech ideas, Arrowhead Pharmaceuticals puts that trade off into sharp focus through its growing RNAi cardiometabolic and CNS pipeline.

"Although plozasiran’s triglyceride and pancreatitis risk reductions support use in high risk severe hypertriglyceridemia, the decision to buy an expensive Priority Review Voucher and pursue STAR program acceleration pulls forward SHTG launch costs into 2026 and 2027. This could weigh on Arrowhead Pharmaceuticals’ earnings before incremental revenue has time to build."

What happens if one still underappreciated swing factor tilts that balance between early launch spending and future profit potential?

If that swing factor matters to you, the full narrative for Arrowhead Pharmaceuticals lays out how Arrowhead Pharmaceuticals could turn front loaded launch pressure into accelerating long term earnings power.

Trulieve Cannabis (TRLV)

Trulieve Cannabis runs a vertically integrated medical cannabis business that fits the Biotech Stocks theme through cultivation, processing, and product development of pharmaceutical grade cannabis products, generating US$1.1b of pharmaceuticals revenue in the United States and carrying a roughly US$2.0b market value.

For biotech focused investors, Trulieve Cannabis brings a different angle to the screen through its medical cannabis production, branded products, and growing U.S. footprint. Together, these elements set up a clear test of how regulatory change can reshape cash generation.

"Federal reclassification of medical marijuana to Schedule III, along with the ability to register with the DEA and deduct ordinary expenses, is expected to reduce the impact of 280E and could free up more cash to support earnings and operating margins over time."

The real swing factor is how one less visible pressure on Trulieve Cannabis’s future profitability responds if that extra cash flow finally starts to bite.

If that pressure on future profitability is on your mind, the full narrative for Trulieve Cannabis shows how Trulieve Cannabis could turn regulatory shifts into accelerating cash generation.

Seeking Alternatives Before The Crowd?

Fresh ideas move first. Once momentum builds and prices start flying, early entry points can disappear quickly. Scan these curated lists now and review them early.

• Spot cash rich operators that maintain strong balance sheets through turbulence by reviewing the list of solid balance sheet and fundamentals (24 results) while it is still under the radar for now.
• Track businesses involved in the AI build out by using the 54 AI infrastructure stocks while it is still gaining attention.
• Identify income-focused opportunities that can support a portfolio’s cash needs through the 5 dividend fortresses while a broad range of options is still available.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com